Physician profile
Michael A Maschek
NPI 1982624433
$4,356.57
in general payments reported to CMS, 2019-2025
9 companies · $2,829 in 2025
The $2,829 reported for 2025 was more than what 88% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,487 · 2024: $40.51 · 2025: $2,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,325 · Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,324.97 |
| Food and Beverage | $1,031.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,318.48 | 2023 | |
| Medtronic, INC. | $1,005.58 | 2025 | Venaseal |
| Solventum Corporation | $912.74 | 2024-2025 | Prevena, V.A.C. Veraflo, Activ.A.C. |
| Biotissue Holdings INC. | $873.70 | 2025 | |
| Depuy Synthes Sales INC. | $168.59 | 2023 | Dynaforce, Foot Osteotomy Wedge System, Na |
| Ossur Americas, INC. | $27.65 | 2025 | |
| Kerecis Limited | $16.84 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Paratek Pharmaceuticals, INC. | $16.68 | 2025 | Nuzyra |
| Aroa Biosurgery Incorporated | $16.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maschek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.